[go: up one dir, main page]

MX2017006022A - Inhibicion de ornitina aminotransferasa con analogos gaba para el tratamiento de carcinoma hepatocelular. - Google Patents

Inhibicion de ornitina aminotransferasa con analogos gaba para el tratamiento de carcinoma hepatocelular.

Info

Publication number
MX2017006022A
MX2017006022A MX2017006022A MX2017006022A MX2017006022A MX 2017006022 A MX2017006022 A MX 2017006022A MX 2017006022 A MX2017006022 A MX 2017006022A MX 2017006022 A MX2017006022 A MX 2017006022A MX 2017006022 A MX2017006022 A MX 2017006022A
Authority
MX
Mexico
Prior art keywords
treatment
hepatocellular carcinoma
inhibition
ornithine aminotransferase
gaba analogues
Prior art date
Application number
MX2017006022A
Other languages
English (en)
Inventor
Ilan Yaron
B Silverman Richard
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of MX2017006022A publication Critical patent/MX2017006022A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Se describen métodos terapéuticos que se relacionan con el uso de compuestos inhibidores de GABA-AT para el tratamiento de carcinoma hepatocelular.
MX2017006022A 2014-11-07 2015-11-09 Inhibicion de ornitina aminotransferasa con analogos gaba para el tratamiento de carcinoma hepatocelular. MX2017006022A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462076980P 2014-11-07 2014-11-07
PCT/US2015/059738 WO2016073983A2 (en) 2014-11-07 2015-11-09 Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
MX2017006022A true MX2017006022A (es) 2017-11-17

Family

ID=55910047

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006022A MX2017006022A (es) 2014-11-07 2015-11-09 Inhibicion de ornitina aminotransferasa con analogos gaba para el tratamiento de carcinoma hepatocelular.

Country Status (9)

Country Link
US (1) US9603820B2 (es)
EP (1) EP3215144B1 (es)
JP (1) JP6867949B2 (es)
AU (1) AU2015342801A1 (es)
CA (1) CA2966642C (es)
ES (1) ES2882126T3 (es)
IL (1) IL252042B (es)
MX (1) MX2017006022A (es)
WO (1) WO2016073983A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210009306A (ko) * 2018-03-29 2021-01-26 오비드 테라퓨틱스 인크. 눈 장애의 치료에서 (1s, 3s)-3-아미노-4-(디플루오로메틸리덴)시클로펜탄-1-카르복실산 및 (s)-3-아미노-4-(디플루오로메틸에닐)시클로펜트-1-엔-1-카르복실산의 용도
US10822301B2 (en) 2018-04-12 2020-11-03 Northwestern University 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase
CN117550990A (zh) 2018-05-25 2024-02-13 西北大学 用于合成(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸的工艺
CA3102786A1 (en) 2018-06-07 2019-12-12 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigab atrin in the treatment of developmental disorders
WO2020176511A1 (en) * 2019-02-25 2020-09-03 Northwestern University Analogs of 3-amino-4-(propan-2-ylidene) cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity
US11078153B2 (en) * 2019-04-03 2021-08-03 Northwestern University 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase
US11993569B2 (en) 2020-01-23 2024-05-28 Northwestern University 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases
JP2024510422A (ja) * 2021-03-03 2024-03-07 ノースウェスタン ユニバーシティ ヒトオルニチンアミノトランスフェラーゼの選択的不活化剤としての３－アミノ－４，４－ジハロシクロペンタ－１－エンカルボン酸
WO2022223969A1 (en) * 2021-04-20 2022-10-27 Bicycletx Limited Bicyclic peptide ligands specific for p-selectin
AU2022331568A1 (en) * 2021-08-19 2024-03-14 N1 Life, Inc. Taxol conjugate compounds, pharmaceutical compositions comprising the same, and methods for their use
WO2024196851A1 (en) * 2023-03-17 2024-09-26 Northwestern University Bicyclic compounds as inactivators of oat and gaba-at

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
IL177609A (en) * 2006-08-21 2015-11-30 Yaron Ilan Use of gobacoline or its analogue to produce a drug to treat liver carcinoma

Also Published As

Publication number Publication date
IL252042B (en) 2020-05-31
US9603820B2 (en) 2017-03-28
WO2016073983A2 (en) 2016-05-12
ES2882126T3 (es) 2021-12-01
WO2016073983A3 (en) 2016-08-11
US20160128958A1 (en) 2016-05-12
JP2017533964A (ja) 2017-11-16
EP3215144A4 (en) 2018-06-20
AU2015342801A1 (en) 2017-05-18
IL252042A0 (en) 2017-06-29
JP6867949B2 (ja) 2021-05-12
CA2966642A1 (en) 2016-05-12
EP3215144B1 (en) 2021-04-28
EP3215144A2 (en) 2017-09-13
CA2966642C (en) 2023-03-28

Similar Documents

Publication Publication Date Title
MX2017006022A (es) Inhibicion de ornitina aminotransferasa con analogos gaba para el tratamiento de carcinoma hepatocelular.
IL285154A (en) Therapeutic inhibitor of lactate dehydrogenase and their factors
IL254722A0 (en) Indoleamine 3,2-dioxygenase inhibitors for cancer treatment
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
IL273585A (en) Therapeutic methods related to HSP90 inhibitors
IL241322A0 (en) Indoleamine 2, 3-dioxygenase (ido) inhibitors
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
SG11201708034SA (en) Methods of administering glutaminase inhibitors
MX2017006464A (es) Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
GEP20186864B (en) Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
PH12017500747A1 (en) Heterocyclic compound
IL249502A0 (en) Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
IL264950B1 (en) Combined treatments for the treatment of malignant liver cell carcinoma
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MX2017003020A (es) Compuestos de dipeptidil-cetoamida y su uso para el tratamiento y/o la prevencion de la acumulacion de grasa.
ZA201408372B (en) Therapeutic biologic for treatment of hepatocellular carcinoma
IN2014DE00822A (es)